Close Menu

NEW YORK – Molecular diagnostic assay developer SpeeDx plans to expand into host-response biomarker testing with a single biomarker called interferon alpha inducible protein 27, or IFI27. The Sydney, Australia-based firm expects to develop the biomarker into a PCR assay called Insignia intended for triaging COVID-19 patients in 2021, and is also developing its own SARS-CoV-2 tests.

Changes in gene expression in response to infection can differ depending on whether a person is infected by a virus or bacteria, in some cases in anticipation of symptoms.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.